Last reviewed · How we verify
OGT918
At a glance
| Generic name | OGT918 |
|---|---|
| Sponsor | National Eye Institute (NEI) |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Fall
- Headache
- COVID-19
- Arthralgia
- Nasopharyngitis
- Myalgia
- DIARRHOEA
- Back pain
- Pain in extremity
- Diarrhea
- Nausea
- Musculoskeletal pain
Key clinical trials
- A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease (PHASE2)
- A Global Prospective Observational Registry of Patients With Pompe Disease
- A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD) (PHASE3)
- A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18 (PHASE3)
- Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the F508del Mutation (PHASE2, PHASE3)
- ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD (PHASE3)
- First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221 (PHASE1, PHASE2)
- Effects of Miglustat Therapy on Infantile Type of Sandhoff and Taysachs Diseases (EMTISTD) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OGT918 CI brief — competitive landscape report
- OGT918 updates RSS · CI watch RSS
- National Eye Institute (NEI) portfolio CI